Abstract 55P
Background
Clinical efficacy of CAR-T cells in solid tumors has been limited due to poor expansion and survival. Most CAR constructs provide signal 1 and 2. Current strategies for providing signal 3 mainly rely on constitutive interleukin signaling, while achieving inducible signaling remains a challenging and highly pursued goal in the field. We hypothesized that adding the intracellular domain of the IL-7 cytokine receptor or its activation motifs to induce signal 3 upon antigen recognition would enhance CAR-T cell activation/persistence.
Methods
CCRs were designed by fusing a scFv to the IL-7Rα intracellular domain with the IL-7Rα or CD8 transmembrane domain. We also created second-generation ICOS or CD28-based CARs incorporating IL-7Rα motifs in different conformations. Construct expression and functionality were assessed in vitro and in vivo.
Results
CCRs were efficiently expressed on the T-cell membrane. In single transduction, CCRs failed to induce STAT5 signaling upon antigen recognition unlike a previously described constitutively active IL-7R (C7R). When the extracellular domain of the C7R was replaced by a scFv, STAT5 activation was not complete, suggesting either some steric concerns or that optimization of the CCR extracellular domain may be needed for correct homodimerization. In co-transduction with a CAR, CCRs did not provide a cytotoxic nor a proliferative advantage. Next, we explored the addition of IL-7Rα signaling motifs within a CAR construct. In vitro, we observed differences in terms of expression and cytotoxicity among the different constructs. Using a model of continuous antigen exposure, some IL7R-based constructs revealed enhanced cytotoxicity compared to the control. In vivo, IL7-based CARs behaved similarly to the control CAR, showing no clear advantage in terms of antitumor activity.
Conclusions
By generating and testing several conformations of IL-7R-based CARs and CCRs, we demonstrate that when IL-7Rα signaling domains are included in these receptors they lack signaling upon antigen recognition. Further analysis of CCR homo/heterodimerization with the IL-2Rɣ will be presented. We believe that these findings may shed light on dynamics of cytokine signaling and allow the design of an inducible CCR.
Legal entity responsible for the study
The authors.
Funding
Asociación Española Contra el Cáncer.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
146P - Neoadjuvant adebrelimab combined with chemotherapy for adenocarcinoma of esophagogastric junction: A single-arm, single-center, phase II clinical trial
Presenter: Jinqiang Liu
Session: Poster Display session
Resources:
Abstract
147P - Serplulimab combined with chemotherapy in the neoadjuvant treatment of resectable oesophageal squamous cell carcinoma: A single-arm phase II trial
Presenter: Zixiang Wu
Session: Poster Display session
Resources:
Abstract
148P - Neoadjuvant camrelizumab plus metronomic chemotherapy in patients with advanced esophageal squamous cell carcinomas: A randomized phase II trial
Presenter: JIE LIU
Session: Poster Display session
Resources:
Abstract
149P - Toripalimab and chemotherapy as first line combination in advanced thymic carcinoma: A prospective, single-arm, phase II trial
Presenter: Kai Zhu
Session: Poster Display session
Resources:
Abstract
150P - Interim results of the multicenter phase II study on induction pembrolizumab plus chemotherapy followed by radiotherapy in locally advanced head and neck cancer
Presenter: Tatiana Antonova
Session: Poster Display session
Resources:
Abstract
151P - Anti-tumor T cell response and immunoselection under combined GARP:TGF-?1/PD-1 blockade
Presenter: Grégoire de Streel
Session: Poster Display session
Resources:
Abstract
152P - TACTI-003 Cohort B: Eftilagimod alpha (Soluble LAG-3) and pembrolizumab in first-line recurrent or metastatic head & neck squamous cell carcinoma with PD-L1 negative
Presenter: Martin Forster
Session: Poster Display session
Resources:
Abstract
153P - Combination of Tim-3 blockade TQB2618 with PD-1 blockade for patients with immunotherapy-resistant recurrent/metastatic nasopharyngeal carcinoma (R/M NPC): Preliminary results from a phase II study
Presenter: Cheng Xu
Session: Poster Display session
Resources:
Abstract
154P - Casdozokitug (casdozo, CHS-388), a first-in-class IL-27 antagonistic antibody, as monotherapy in treatment-refractory non-small cell lung cancer (NSCLC)
Presenter: Aung Naing
Session: Poster Display session
Resources:
Abstract
155P - Tarlatamab for patients with small cell lung cancer: 6-8 hour outpatient vs 48 hour inpatient monitoring in cycle 1
Presenter: Anne Chiang
Session: Poster Display session
Resources:
Abstract